# Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer

Source: https://onco.cc/trials/nct06202313/  
OnCo record `nct06202313` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cadonilimab and eribulin in triple-negative breast cancer, run by Shengjing Hospital, not yet recruiting.

## Summary

Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer is a phase 2, randomised interventional study registered as NCT06202313 by Shengjing Hospital, with a registry enrolment figure of 128 participants, started 2024-02-10 and due to reach its primary completion in 2025-12-30. Interventions recorded: Cadonilimab; Eribulin. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Recurrent or metastatic incurable triple negative breast cancer confirmed by histology and/or cytology". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06202313
- Phase: 2
- Setting: A Multicenter, Randomized, Controlled, Open Label Clinical Study on the Treatment of Recurrent or Metastatic Triple Negative Breast Cancer With Cadonilimab Combined With Eribulin Versus Eribulin Alone
- Sponsor: Shengjing Hospital
- Enrolled: 128

## Sources

- ClinicalTrials.gov NCT06202313: https://clinicaltrials.gov/study/NCT06202313

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/), [Eribulin](https://onco.cc/drugs/eribulin/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06202313.json